News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Jun 18, 2026 at 22:08 Big Tech Rising Hot

FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

In February, a Trump official refused to review the vaccine.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed. In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine. Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good. Read full article Comments

Stay on the signal

Follow FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Advisors, Ars Technica, and FDA, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 18, 2026 at 22:08 Ars Technica

FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

In February, a Trump official refused to review the vaccine.

Jun 18, 2026 at 21:21 Ars Technica

As China looms, Taiwan makes more drones for defense and the US military

Taiwan's drone spending plans for defense could also boost business overseas.

Jun 18, 2026 at 20:49 Ars Technica

NASA asks Northrop Grumman to stop working on lunar HALO module

"We are reassigning most affected employees across existing opportunities and programs."

Jun 18, 2026 at 19:41 Ars Technica

Apple patches high-severity eavesdropping vulnerability in Beats Studio Buds

The vulnerability, disclosed 12 months ago, affects multiple manufacturers.

Jun 18, 2026 at 18:19 Ars Technica

After Senate vote, Trump admin backs off plans to kill ocean monitoring

It's unclear whether the system is currently intact.

Jun 18, 2026 at 17:42 Ars Technica

Before SpaceX IPO, investors in China secretly acquired stakes

One previously unreported SpaceX investor has ties to Chinese military contractors.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page